Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomy.

ABSTRACT:

Objectives

Intravenous or oral steroid administration in patients with biliary atresia (BA) after Kasai hepatoportoenterostomy (HPE) is commonly practiced, however, the benefits remain controversial. Some studies suggest no positive effects while risking steroid associated side effects. Rectal application of glucocorticoids has so far only been assessed by our group with promising short-term results. We now aim to evaluate the impact of rectal budesonide administration on long-term native liver survival in patients undergoing HPE for BA.

Methods

We performed a retrospective cohort study and included all patients after HPE who received rectal budesonide (2 mg) for 3 months from 2011 to 2022, compared to a historical control group without any glucocorticoid treatment. Jaundice

SUBMITTER: Langreen S 

PROVIDER: S-EPMC12408950 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature